ETON
Eton Pharmaceuticals, Inc.
Biotechnology
Market Cap$890M
5Y Perf.+496.0%
Build Your Comparison
Side-by-side financial analysisETON
AVDL
JPM
Try popular comparisons:
Stock Comparison
ETON vs AVDL vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
AVDL
Avadel Pharmaceuticals plc
Drug Manufacturers - Specialty & Generic
Market Cap$2.10B
5Y Perf.+166.7%
JPM
JPMorgan Chase & Co.
Banks - Diversified
Market Cap$908.57B
5Y Perf.+245.8%
ETON vs AVDL vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ETON |  AVDL |  JPM |
|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Banks - Diversified |
| Market Cap | $890M | $2.10B | $908.57B |
| Revenue (TTM) | $87M | $249M | $280.33B |
| Net Income (TTM) | $-1M | $-278K | $57.05B |
| Gross Margin | 54.8% | 94.5% | 60.0% |
| Operating Margin | 2.3% | 1.8% | 25.9% |
| Forward P/E | 40.5x | 28.3x | 14.6x |
| Total Debt | $31M | $2M | $942.38B |
| Cash & Equiv. | $26M | $51M | $343.34B |
ETON vs AVDL vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ETON
AVDL
JPM
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Eton Pharmaceutical… (ETON) | 100 | 596.0 | +496.0% |
| Avadel Pharmaceutic… (AVDL) | 100 | 266.7 | +166.7% |
| JPMorgan Chase & Co. (JPM) | 100 | 345.8 | +245.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ETON vs AVDL vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JPM leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Avadel Pharmaceuticals plc is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
ETON
Eton Pharmaceuticals, Inc.
The Long-Run Compounder
ETON is the clearest fit if your priority is long-term compounding.
- 419.7% 10Y total return vs JPM's 481.2%
- +137.1% vs JPM's +20.9%
Best for: long-term compounding
AVDL
Avadel Pharmaceuticals plc
The Growth Play
AVDL is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 5.0%, EPS growth 74.5%
- Lower volatility, beta 0.15, Low D/E 2.3%, current ratio 2.75x
- Beta 0.15, current ratio 2.75x
Best for: growth exposure and sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick
JPM carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 15 yrs, beta 0.87, yield 1.8%
- Lower P/E (14.6x vs 28.3x)
- 20.4% margin vs ETON's -1.7%
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  AVDL | 5.0% revenue growth vs JPM's 3.3% |
| Value |  JPM | Lower P/E (14.6x vs 28.3x) |
| Quality / Margins | JPM | 20.4% margin vs ETON's -1.7% |
| Stability / Safety | AVDL | Beta 0.15 vs JPM's 0.87, lower leverage |
| Dividends | JPM | 1.8% yield; 15-year raise streak; the other 2 pay no meaningful dividend |
| Momentum (1Y) |  ETON | +137.1% vs JPM's +20.9% |
| Efficiency (ROA) | JPM | 1.3% ROA vs ETON's -1.5%, ROIC 4.5% vs 0.2% |
ETON vs AVDL vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
FY 2025
ETON vs AVDL vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJPMLAGGINGAVDL
AVDLAvadel Pharmaceutical…
0leads
ETONEton Pharmaceuticals,…
1leads
JPMJPMorgan Chase & Co.
4leads
6 Total Categories
CATEGORYLEADERvs ETONvs AVDLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JPM3/6
Valuation MetricsMultiples, price ratios, and targets
JPM5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JPM5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ETON5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
JPM1/1
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 3224.7x ETON's $87M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ETON's -1.7%. On growth, AVDL holds the edge at +54.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ETONEton Pharmaceutic… | AVDLAvadel Pharmaceut… | JPMJPMorgan Chase & … |
|---|---|---|---|
| RevenueTrailing 12 months | $87M | $249M | $280.3B |
| EBITDAEarnings before interest/tax | $5M | $8M | $81.4B |
| Net IncomeAfter-tax profit | -$1M | -$278,000 | $57.0B |
| Free Cash FlowCash after capex | $15M | $35M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +54.8% | +94.5% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +2.3% | +1.8% | +25.9% |
| Net MarginNet income ÷ Revenue | -1.7% | -0.1% | +20.4% |
| FCF MarginFCF ÷ Revenue | +17.8% | +14.2% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +40.4% | +54.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +185.5% | +100.7% | +16.0% |
JPM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
JPM leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, JPM's 18.5x EV/EBITDA is more attractive than ETON's 217.4x.
| Metric | ETONEton Pharmaceutic… | AVDLAvadel Pharmaceut… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Market CapShares × price | $890M | $2.1B | $908.6B |
| Enterprise ValueMkt cap + debt − cash | $895M | $2.1B | $1.51T |
| Trailing P/EPrice ÷ TTM EPS | -191.06x | -42.43x | 16.22x |
| Forward P/EPrice ÷ next-FY EPS est. | 40.46x | 28.28x | 14.60x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.92x |
| EV / EBITDAEnterprise value multiple | 217.39x | — | 18.52x |
| Price / SalesMarket cap ÷ Revenue | 11.13x | 12.44x | 3.25x |
| Price / BookPrice ÷ Book value/share | 33.42x | 27.88x | 2.51x |
| Price / FCFMarket cap ÷ FCF | 87.30x | — | 9.01x |
JPM leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
JPM leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-6 for ETON. AVDL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), ETON scores 5/9 vs AVDL's 4/9, reflecting solid financial health.
| Metric | ETONEton Pharmaceutic… | AVDLAvadel Pharmaceut… | JPMJPMorgan Chase & … |
|---|---|---|---|
| ROE (TTM)Return on equity | -5.7% | -0.3% | +15.9% |
| ROA (TTM)Return on assets | -1.5% | -0.2% | +1.3% |
| ROICReturn on invested capital | +0.2% | -76.3% | +4.5% |
| ROCEReturn on capital employed | +0.1% | -34.9% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 5 |
| Debt / EquityFinancial leverage | 1.19x | 0.02x | 2.60x |
| Net DebtTotal debt minus cash | $5M | -$50M | $599.0B |
| Cash & Equiv.Liquid assets | $26M | $51M | $343.3B |
| Total DebtShort + long-term debt | $31M | $2M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | 0.96x | 0.66x | 0.74x |
JPM leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ETON leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ETON five years ago would be worth $54,314 today (with dividends reinvested), compared to $23,548 for JPM. Over the past 12 months, ETON leads with a +137.1% total return vs JPM's +20.9%. The 3-year compound annual growth rate (CAGR) favors ETON at 101.7% vs AVDL's 14.3% — a key indicator of consistent wealth creation.
| Metric | ETONEton Pharmaceutic… | AVDLAvadel Pharmaceut… | JPMJPMorgan Chase & … |
|---|---|---|---|
| YTD ReturnYear-to-date | +99.8% | +0.6% | +0.8% |
| 1-Year ReturnPast 12 months | +137.1% | +132.2% | +20.9% |
| 3-Year ReturnCumulative with dividends | +720.2% | +49.4% | +138.8% |
| 5-Year ReturnCumulative with dividends | +443.1% | +175.7% | +135.5% |
| 10-Year ReturnCumulative with dividends | +419.7% | +127.8% | +481.2% |
| CAGR (3Y)Annualised 3-year return | +101.7% | +14.3% | +33.7% |
ETON leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AVDL and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
AVDL is the less volatile stock with a 0.15 beta — it tends to amplify market swings less than JPM's 0.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 96.2% from its 52-week high vs ETON's 91.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ETONEton Pharmaceutic… | AVDLAvadel Pharmaceut… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.49x | 0.15x | 0.87x |
| 52-Week HighHighest price in past year | $35.58 | $23.57 | $338.09 |
| 52-Week LowLowest price in past year | $13.09 | $8.52 | $269.72 |
| % of 52W HighCurrent price vs 52-week peak | +91.3% | +91.8% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 61.5 | 61.8 | 72.1 |
| Avg Volume (50D)Average daily shares traded | 364K | 0 | 7.4M |
Evenly matched — AVDL and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
JPM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ETON as "Buy", AVDL as "Buy", JPM as "Buy". Consensus price targets imply 75.5% upside for ETON (target: $57) vs -1.0% for AVDL (target: $21). JPM is the only dividend payer here at 1.83% yield — a key consideration for income-focused portfolios.
| Metric | ETONEton Pharmaceutic… | AVDLAvadel Pharmaceut… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $57.00 | $21.43 | $339.75 |
| # AnalystsCovering analysts | 6 | 14 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.8% |
| Dividend StreakConsecutive years of raises | 1 | — | 15 |
| Dividend / ShareAnnual DPS | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.8% |
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway
JPM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). ETON leads in 1 (Total Returns). 1 tied.
Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...
ETON vs AVDL vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ETON or AVDL or JPM a better buy right now?
For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.
8% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Eton Pharmaceuticals, Inc. (ETON) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ETON or AVDL or JPM?
On forward P/E, JPMorgan Chase & Co.
is actually cheaper at 14. 6x.
03Which is the better long-term investment — ETON or AVDL or JPM?
Over the past 5 years, Eton Pharmaceuticals, Inc.
(ETON) delivered a total return of +443. 1%, compared to +135. 5% for JPMorgan Chase & Co. (JPM). Over 10 years, the gap is even starker: JPM returned +481. 2% versus AVDL's +127. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ETON or AVDL or JPM?
By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.
15β versus JPMorgan Chase & Co. 's 0. 87β — meaning JPM is approximately 470% more volatile than AVDL relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — ETON or AVDL or JPM?
By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.
8% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Avadel Pharmaceuticals plc grew EPS 74. 5% year-over-year, compared to -13. 3% for Eton Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ETON or AVDL or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -28. 9% for Avadel Pharmaceuticals plc — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -25. 1% for AVDL. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ETON or AVDL or JPM more undervalued right now?
On forward earnings alone, JPMorgan Chase & Co.
(JPM) trades at 14. 6x forward P/E versus 40. 5x for Eton Pharmaceuticals, Inc. — 25. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ETON: 75. 5% to $57. 00.
08Which pays a better dividend — ETON or AVDL or JPM?
In this comparison, JPM (1.
8% yield) pays a dividend. ETON, AVDL do not pay a meaningful dividend and should not be held primarily for income.
09Is ETON or AVDL or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Both have compounded well over 10 years (JPM: +481. 2%, ETON: +419. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ETON and AVDL and JPM?
These companies operate in different sectors (ETON (Healthcare) and AVDL (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ETON is a small-cap high-growth stock; AVDL is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ETON, AVDL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.